Commercial Prognostic Tests for Prostate Cancer May Not Be Accurate in African American Men
PHILADELPHIA — Commercial gene expression tests that guide treatment decisions for prostate cancer may not accurately predict risk of...
Search/Filter
Loading...
Oncotype DX Breast Recurrence Score Reveals Sex-related Differences in Mortality Prediction in Patients With Early-stage ER-positive Breast Cancer
PHILADELPHIA — The associations of breast cancer recurrence scores (RS) with mortality measured using Oncotype DX, a commercial diagnostic...
Long-term Survival Rate for Subset of Patients With Advanced Melanoma Following BRAF- and MEK-targeted Treatment Combination Higher Than Historical Rate
PHILADELPHIA — Almost 40 percent of patients with metastatic melanoma harboring BRAF V600E mutations who were treated with a...
Antibody-Drug Conjugate Shows Early Promise in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
PHILADELPHIA – ADCT-402, an investigational antibody-drug conjugate, showed signs of clinical activity in patients with relapsed/refractory B-cell non-Hodgkin lymphoma,...
AACR Applauds Nomination of Stephen M. Hahn, MD, as FDA Commissioner
PHILADELPHIA — The American Association for Cancer Research (AACR), the world’s first and largest cancer research organization dedicated to...
AACR Project GENIE Begins Five-year Collaborative Research Project with $36 Million in New Funding
The project will further enhance a unique, real-world clinico-genomic dataset through the joint efforts of nine biopharmaceutical companies PHILADELPHIA...
Award Winners Named for the 2019 San Antonio Breast Cancer Symposium
SAN ANTONIO — The San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR), an...
Tipifarnib Shows Promising Clinical Activity in Patients With HRAS-mutant Head and Neck Cancer
BOSTON – The investigational farnesyl transferase inhibitor tipifarnib yielded durable objective responses in patients with recurrent and metastatic head...
MRTX849 Shows Clinical Activity in Patients With KRAS G12C-mutant Solid Cancers
BOSTON The investigational KRAS G12C inhibitor MRTX849 yielded clinical responses in patients with non-small cell lung cancer (NSCLC) and...
Selumetinib Shows Clinical Benefit in Adult Patients with Neurofibromatosis Type 1-Associated Plexiform Neurofibromas
BOSTON – The investigational MEK inhibitor selumetinib showed clinical responses in adult patients with neurofibromatosis type 1-associated plexiform neurofibromas,...